We are evaluating AI for chronic disease monitoring at home. What vendors should we compare?
Data as of Sep 21, 2026 · Based on 52 AI responses from ChatGPT Search and Google AI Mode · See how Parse measures this
Data as of Sep 21, 2026 · Based on 52 AI responses from ChatGPT Search and Google AI Mode · See how Parse measures this
Source | Citation share |
|---|---|
Choosing the Right AI-Powered Remote Care Platformhttps://blog.prevounce.com/choosing-the-right-ai-powered-remote-care-platform-what-to-look-for | 3% |
 Precision management in chronic disease: An AI empowered perspective on medicine-engineering crossover - PMChttps://pmc.ncbi.nlm.nih.gov/articles/PMC11914802/ | 2% |
 Clinical AI for Chronic Carehttps://www.cadence.care/ | 2% |
 Platformhttps://biofourmis.com/platform | 1% |
Identifying the Best Remote Patient Monitoring (RPM) Companies in ...https://blog.prevounce.com/identifying-the-best-remote-patient-monitoring-companies-a-2026-review-across-chronic-care-post-acute-and-hospital-at-home | 1% |
 Top Remote Patient Monitoring Companies in 2026 | HealthArchttps://www.healtharc.io/blogs/top-11-remote-patient-monitoring-companies/ | 1% |
 Top 31 Remote Patient Monitoring startups in USAhttps://www.medicalstartups.org/top/remote-patient-monitoring/USA/ | 1% |
 AI-Powered Remote Patient Monitoring | How AI Improves Care and Outcomes | Tellihealthhttps://tellihealth.com/resources/ai-powered-remote-patient-monitoring | 1% |
 Which EHR Uses AI Best? Here's the Breakdownhttps://www.youtube.com/watch | 1% |
Remote patient monitoring AI companies comparedhttps://aihealthindex.io/categories/remote-monitoring | 1% |
When evaluating AI-driven remote patient monitoring (RPM) and chronic disease management platforms for the home, you are looking at systems that ingest multi-modal data (wearables, connected scales, glucose meters, patient-reported symptoms) and use predictive analytics to flag decompensation before it requires acute…
When evaluating AI-driven remote patient monitoring (RPM) and chronic disease management platforms for the home, you are looking at systems that ingest multi-modal data (wearables, connected scales, glucose meters, patient-reported symptoms) and use predictive analytics to flag decompensation before it requires acute intervention.
The leading vendors in this space approach home-based chronic care with different core strengths, ranging from deep clinical analytics engines to massive virtual care delivery integration.
When vetting these or other vendors, structure your evaluation around these pillars:
To help narrow down this list, let me know:
For a U.S. health-system evaluation of **AI-enabled chronic-disease monitoring at home**, I’d build the comparison around several different vendor archetypes rather than treating “AI RPM” as one market. ### Vendors to put in the initial RFP - **Cadence** — AI-supported, full-service chronic-care/RPM model. Its current…
For a U.S. health-system evaluation of AI-enabled chronic-disease monitoring at home, I’d build the comparison around several different vendor archetypes rather than treating “AI RPM” as one market.
I'd also consider a device-centric benchmark such as Dexcom or Abbott if diabetes/CGM is a major part of the program. The FDA's current authorized-device database includes multiple home-capable CGM products from both companies.
| Dimension | Questions to ask vendors |
|---|---|
| Conditions | HTN, HF, diabetes, COPD, CKD, obesity? Which are actually live vs roadmap? |
| Sensors | BP, weight, SpO₂, glucose, ECG, temperature, activity? Continuous vs intermittent? |
| AI | What exactly is AI doing—risk prediction, alert prioritization, care-plan generation, patient coaching, autonomous intervention? |
| Clinical response | Who responds to an alert? Vendor clinicians, your clinicians, or both? What happens after hours? |
| Autonomy | What percentage of alerts/actions are handled without human intervention, and how is that measured? |
| Evidence | Peer-reviewed outcomes, hospitalization/readmission data, adherence, mortality, total cost of care? |
| Regulatory | Which algorithms/devices are FDA-authorized, and for precisely what intended use? Don't equate an FDA-cleared sensor with an FDA-cleared predictive algorithm. U.S. Food and Drug Administration |
| EHR integration | Epic/Cerner/FHIR/HL7, bidirectional orders/results, clinician workflow, SSO? |
| Patient experience | Cellular vs Wi-Fi, smartphone requirement, device setup, adherence, accessibility, caregiver support? |
| Economics | PMPM, implementation fees, device costs, clinical staffing, RPM/CCM reimbursement, shared savings/risk? |
| AI governance | Model documentation, validation population, drift monitoring, audit logs, human override, explainability, data retention, model/vendor changes? |
| Scale | Can it go from 1,000 to 50,000+ patients without proportional clinical staffing? |
One particularly important distinction is “AI-enabled monitoring” versus “AI-enabled care.” Cadence, for example, combines monitoring with a clinical-services model, whereas a platform vendor may primarily provide the technology for your clinical organization to operate. Those are substantially different implementations and economics.
Also, FDA's current digital-health framework makes it worthwhile to request the exact FDA authorization/clearance number and intended use for every AI/device component, rather than accepting a generic claim that the platform is “FDA cleared.” The FDA maintains separate current lists for AI-enabled devices and sensor-based digital-health devices.
If you tell me your target diseases (e.g., HF + HTN + diabetes), patient volume, and whether you want software-only or a fully managed clinical service, I can turn this into a 6–8 vendor shortlist with a side-by-side RFP scorecard and suggested pilot design.
When evaluating AI-driven platforms for home-based chronic disease monitoring, you should compare vendors across different tiers—ranging from `specialized digital health and predictive analytics companies to massive medical device and enterprise health ecosystems`. Here are the key vendors to compare, categorized by…
When evaluating AI-driven platforms for home-based chronic disease monitoring, you should compare vendors across different tiers—ranging from specialized digital health and predictive analytics companies to massive medical device and enterprise health ecosystems.
Here are the key vendors to compare, categorized by their core strengths:
To help narrow down this list, could you tell me:
If you're evaluating **AI for at-home chronic disease monitoring**, I’d compare vendors across three distinct models rather than treating all “RPM” companies as equivalent: Vendor | Best fit | AI / analytics | Clinical service | Particularly relevant conditions --- | --- | --- | --- | ---
If you're evaluating AI for at-home chronic disease monitoring, I’d compare vendors across three distinct models rather than treating all “RPM” companies as equivalent:
| Vendor | Best fit | AI / analytics | Clinical service | Particularly relevant conditions |
|---|---|---|---|---|
| Cadence | AI-enabled chronic care at scale | Risk detection, AI agents, longitudinal vitals/symptoms/medications | Yes — embedded clinical team | Hypertension, diabetes, HF, COPD |
| Biofourmis | Higher-acuity / continuous monitoring | Personalized physiological baselines, deterioration detection | Yes | HF, post-acute, oncology, complex chronic |
| Current Health | Hospital-at-home / transitional care | Continuous physiologic monitoring and risk detection | Platform + services/logistics | HF, COPD, post-acute, hospital-at-home |
| HealthSnap | Conventional RPM/CCM infrastructure | Risk stratification and workflow automation | Primarily platform-oriented | Hypertension, diabetes, obesity, cardiometabolic |
| Huma | Multi-condition digital care | Predictive analytics, patient monitoring | Configurable | Cardiovascular, respiratory, metabolic and other pathways |
| Health Recovery Solutions | Health-system RPM / post-acute | Automated monitoring and alerts | Services/logistics available | Broad chronic + post-discharge |
| Vivify Health | Enterprise virtual care | Risk/alert workflows | Platform + connected devices | Broad chronic, post-acute |
| Rimidi | Clinician-led cardiometabolic care | Population risk and clinical decision support | No comparable full clinical-service model | Diabetes, CVD, obesity |
| Glooko | Diabetes-specific monitoring | Glucose analytics and decision support | Primarily technology | Diabetes |
| Lark Health | AI coaching / lower-acuity chronic care | Conversational AI and behavioral coaching | Virtual care | Diabetes, hypertension, weight/metabolic |
Current market reporting particularly identifies Cadence, Biofourmis, Current Health, HealthSnap, HRS, Vivify and Rimidi as meaningful RPM/chronic-care competitors.
If this is an enterprise health-system evaluation, I'd put Cadence, Biofourmis, Current Health, HealthSnap and HRS/Vivify into the first competitive round.
The important distinction is that Cadence is much closer to “AI + care delivery” than a conventional RPM software vendor. Its platform monitors vitals, symptoms, medications and engagement, uses AI agents to identify risk, and has a clinical team that can intervene and perform physician-led medication titration.
Biofourmis is particularly interesting if you care about continuous physiologic data and early deterioration. Its platform creates patient-specific baselines from biosensor data and supports configurable disease/acuity pathways and clinical escalation.
Current Health is more compelling if your scope extends from chronic disease into hospital-at-home, post-acute and transitional care, with continuous monitoring plus device/logistics infrastructure.
HealthSnap is a better benchmark for a more traditional RPM + CCM software platform, including device integration, care-team coordination and billing infrastructure.
Don't make “AI accuracy” the headline criterion. I'd score vendors on:
That regulatory distinction is especially important: for example, public documentation around Biofourmis distinguishes its FDA-cleared vital-sign monitoring from broader claims about predictive deterioration.
If you tell me whether you're evaluating this for a health system, payer, pharma company, or home-health organization, I can turn this into a 10–15 vendor competitive matrix with pricing model, FDA status, AI capabilities, diseases covered, evidence, integrations, and key strengths/weaknesses.
The important distinction is that Cadence is much closer to “AI + care delivery” than a conventional RPM software vendor. Its platform monitors vitals, symptoms, medications and engagement, uses AI agents to identify risk, and has a clinical team that can intervene and perform physician-led medication titration.
Biofourmis is particularly interesting if you care about continuous physiologic data and early deterioration. Its platform creates patient-specific baselines from biosensor data and supports configurable disease/acuity pathways and clinical escalation.
Current Health is more compelling if your scope extends from chronic disease into hospital-at-home, post-acute and transitional care, with continuous monitoring plus device/logistics infrastructure.
When evaluating home-based chronic disease monitoring with integrated AI, you should compare top remote patient monitoring (RPM) and chronic care management (CCM) vendors like **HealthSnap, BioIntelliSense, ThoroughCare, ChartSpan, and ChronicCareIQ**.[](https://omnimd.com/blog/best-chronic-care-management-software/)…
When evaluating home-based chronic disease monitoring with integrated AI, you should compare top remote patient monitoring (RPM) and chronic care management (CCM) vendors like HealthSnap, BioIntelliSense, ThoroughCare, ChartSpan, and ChronicCareIQ.
Selecting the right vendor requires balancing clinical workflow integration, device interoperability, and AI-driven predictive analytics.
| Vendor | Primary Model | Best Fit For | Core AI & Monitoring Focus |
|---|---|---|---|
| HealthSnap | Hybrid (Software + Navigation) | Larger practices and health systems | Integrated RPM, lifestyle tracking, and virtual care coordination with AI-driven risk-stratification. |
| BioIntelliSense | Medical-grade Wearables + Analytics | Continuous multi-parameter vital sign tracking | Medical-grade biosensors capturing continuous heart rate, respiratory rate, and skin temperature with predictive early-warning analytics. |
| ThoroughCare | Software-only | In-house teams running multiple programs | Comprehensive care coordination, patient engagement, and analytics tracking for CCM and RPM. |
| ChartSpan | Full-service | Practices without care coordinators | Turnkey, fully managed chronic care programs backed by clinical staff extensions and software. |
| ChronicCareIQ | Software | Combined RPM and CCM programs | Automated patient symptom tracking and specialized disease protocols designed for specialty and primary care groups. |
To help narrow down this list, please tell me:
If you’re evaluating **AI for chronic-disease monitoring at home**, I’d compare vendors across three distinct models rather than treating “RPM” as one market: Vendor | Best fit | AI / monitoring angle | Care model --- | --- | --- | ---
If you’re evaluating AI for chronic-disease monitoring at home, I’d compare vendors across three distinct models rather than treating “RPM” as one market:
| Vendor | Best fit | AI / monitoring angle | Care model |
|---|---|---|---|
| Cadence | Hypertension, diabetes, HF, COPD | AI-supported continuous vitals/symptom monitoring, risk detection, care-team recommendations | Full-service clinical care + technology |
| Biofourmis | Complex chronic disease, HF, cardiometabolic, post-acute | Personalized physiological analytics and deterioration detection from continuous data | Technology + clinical/care-delivery services |
| **Current Health / Best Buy Health | Broad home monitoring, hospital-at-home, post-acute | Continuous biosensor data, configurable alerts and analytics | Platform + devices/logistics; clinical model varies |
| Omada Health | Diabetes, hypertension, obesity/cardiometabolic | Personalized digital coaching, connected devices and longitudinal behavior data | Virtual care / digital health, less acute deterioration-focused |
| Health Recovery Solutions | HF, COPD, diabetes, transitions of care | RPM analytics, risk alerts and workflow tools | Technology platform; supports health-system clinical teams |
| Glooko | Diabetes | Connected glucose/device data, patient stratification and diabetes-management analytics | Diabetes-specific digital platform |
| Stel Life | Broad chronic RPM, especially populations with technology barriers | Aggregates BP, weight, glucose, SpO₂, etc.; cellular connectivity | RPM platform/device infrastructure |
Cadence is particularly worth putting in the core RFP: its current offering explicitly combines AI/clinical intelligence with continuous monitoring and a care team, and it is being deployed for hypertension, diabetes and heart failure.
Biofourmis is the stronger comparator if your priority is physiological deterioration prediction and continuous wearable data rather than primarily routine RPM. Its platform says it uses AI-guided algorithms, continuous clinical-device data and personalized care pathways.
Omada belongs in the comparison if your definition of “monitoring” includes longitudinal cardiometabolic management, adherence and behavior change. It supplies connected devices and combines them with coaching and clinical support.
For an enterprise health-system evaluation, I'd start with:
One important 2026 consideration: don't evaluate vendors solely on their AI model. Separate the evaluation into data acquisition → risk prediction → clinical decision support → human escalation → intervention → outcomes. The vendor landscape increasingly mixes AI software with clinical staffing, and those are very different propositions.
Also, the reimbursement model deserves its own diligence workstream. A proposed 2026 CMS policy could materially affect RPM businesses that depend on vendor-employed clinical staff being reimbursed by Medicare.
If you're building an actual vendor scorecard/RFP, I can also give you a 20–30 criterion framework covering AI accuracy, FDA status, false-alert burden, interoperability, patient adherence, clinical workflow, staffing, security, economics, and evidence of reduced admissions.
If you’re evaluating **AI for chronic-disease monitoring at home**, I’d compare vendors across two distinct models: **AI-enabled clinical care programs** (where the vendor supplies monitoring plus clinicians) and **RPM software/platform vendors** (where your organization supplies the clinical operation). ### Shortlist…
If you’re evaluating AI for chronic-disease monitoring at home, I’d compare vendors across two distinct models: AI-enabled clinical care programs (where the vendor supplies monitoring plus clinicians) and RPM software/platform vendors (where your organization supplies the clinical operation).
| Vendor | Best fit | AI / monitoring angle | Key conditions |
|---|---|---|---|
| Cadence | Health systems wanting a largely turnkey program | AI agents monitor vitals, symptoms, medications and engagement, with clinician escalation | HTN, diabetes, HF, COPD |
| Biofourmis / CopilotIQ | Complex, continuous home monitoring | AI-driven personalized physiology/digital biomarkers + care pathways | Cardio, pulmonary, post-acute, broader chronic care |
| Huma | Enterprise digital-care platform | Remote monitoring, digital biomarkers, configurable disease pathways | Broad/multimorbidity |
| HealthSnap | Provider/RPM programs | Automated monitoring and patient engagement | HTN, diabetes, obesity, cardiometabolic |
| 100Plus | Practice-level RPM | AI-assisted care coordination and end-to-end RPM | Multiple chronic conditions |
| Optimize Health | Health systems/practices building their own program | Workflow and clinical-monitoring automation | Multiple chronic conditions |
| Health Recovery Solutions (HRS) | Hospital/home-health programs | Connected devices + patient engagement + clinical workflows | Broad |
| Verily | Payers/employers and population health | AI-enabled chronic-care management through Lightpath | Diabetes, prediabetes, obesity |
| Lark Health | AI-first virtual coaching | AI coaching + connected-device monitoring | Diabetes, hypertension, weight/metabolic health |
The market is changing quickly: for example, Biofourmis and CopilotIQ announced a merger, creating a broader AI-driven in-home-care platform. Biofourmis Cadence is particularly worth including because it combines AI with an embedded clinical team rather than simply handing alerts to your existing staff.
I'd score vendors on these dimensions:
This distinction can dramatically change both economics and implementation burden. Current market comparisons explicitly identify staffing, devices, integrations and clinical scope as major differences between RPM companies. CCNHealth Vironix Health 7. AI transparency and regulatory status
For a health-system procurement, my initial bake-off would be:
I'd also include one incumbent/device-centric solution in the evaluation, because otherwise you risk concluding that an AI vendor is valuable simply because it supplies a nicer monitoring workflow.
One particularly important caveat: don't accept "AI-powered" as evidence of predictive capability. Some vendors' AI is primarily used for workflow, engagement, or alert prioritization rather than predicting clinical deterioration. Even within RPM, the distinction between an FDA-cleared device that measures physiology and an algorithm that predicts an outcome is consequential.
If you tell me your target population (e.g., HF, COPD, diabetes, hypertension or multimorbidity), deployment size, and whether you want software-only vs. turnkey clinical services, I can turn this into a 10–15 vendor comparison matrix with pricing model, FDA status, devices, EHR integration, evidence, AI capabilities, and likely strengths/weaknesses.
Huma
Epic
epic.com
Evaluating AI-driven remote patient monitoring (RPM) and chronic disease management vendors for home use requires looking at how well they combine hardware connectivity, predictive AI analytics, clinical workflow integration, and patient…
Evaluating AI-driven remote patient monitoring (RPM) and chronic disease management vendors for home use requires looking at how well they combine hardware connectivity, predictive AI analytics, clinical workflow integration, and patient engagement.
Vendors in this space generally fall into three categories depending on whether you are looking for enterprise infrastructure, disease-specific specialization, or comprehensive turnkey services.
Key Evaluation Criteria Checklist
When comparing these vendors, consider testing them against the following parameters:
To help narrow down this list, tell me:
If you’re evaluating **AI for at-home chronic disease monitoring**, I’d build the comparison around both **AI capability** and the **care-delivery model**. The market has a meaningful divide between vendors that sell a technology platform and vendors that effectively provide an AI-enabled clinical service. ### Vendors…
If you’re evaluating AI for at-home chronic disease monitoring, I’d build the comparison around both AI capability and the care-delivery model. The market has a meaningful divide between vendors that sell a technology platform and vendors that effectively provide an AI-enabled clinical service.
| Vendor | Best fit | What to evaluate |
|---|---|---|
| Cadence | Hypertension, diabetes, heart failure, COPD | Strong benchmark for AI-driven chronic care; monitors daily vitals and uses AI agents to surface risk and coordinate intervention. Cadence TechTarget |
| Biofourmis | Higher-acuity chronic/post-acute care | Personalized physiological baselines, continuous wearable data, predictive deterioration, and clinical services. It now operates alongside CopilotIQ following their combination. Biofourmis Biofourmis |
| Current Health | Hospital-at-home / complex chronic patients | Passive wearable monitoring, AI-enabled deterioration detection, connected devices and clinical command-center capabilities. Current Health |
| Huma | Broad digital chronic-care programs | Worth including if you want a more configurable software platform rather than a fully outsourced clinical model. |
| Verily | AI-enabled population/chronic care | Particularly interesting if you want AI agents and population-level care management rather than simply RPM alerts. |
| Dimer Health | Chronic disease + virtual clinical care | Useful comparator for the "technology + clinical service" model. |
| HealthSnap | Provider-controlled RPM | Good comparator if your organization wants to retain its own clinical workflows rather than outsource care. |
| Athelas | RPM + home diagnostics | Particularly interesting if home lab testing is part of the strategy; it combines connected monitoring with at-home diagnostics. IntuitionLabs |
A current industry landscape identifies 40 vendors in remote monitoring/chronic-care AI, but the important distinction is that relatively few are true apples-to-apples competitors.
If you're doing a serious enterprise RFP, I'd narrow that to 6–8 vendors:
Don't let the vendors compete primarily on number of devices, dashboards, or "AI-powered" marketing. I'd score them on:
One particularly important distinction: Cadence and Biofourmis are not simply AI software vendors. Their offerings incorporate substantial clinical-service infrastructure, so you should separate the question "whose AI is better?" from "which operating model do we want?"
If you tell me the diseases you're targeting (e.g., CHF, COPD, diabetes, hypertension), patient population, and whether you want to provide the clinical staff yourselves, I can turn this into a vendor scorecard/RFP matrix with ~20 criteria and suggested weighting.
Huma
Epic
epic.com
When evaluating home AI for chronic disease monitoring, you should compare leading remote patient monitoring (RPM) and chronic care management (CCM) vendors like **HealthSnap, BioIntelliSense, ThoroughCare, and ChronicCareIQ**.[](https://omnimd.com/blog/best-chronic-care-management-software/)…
When evaluating home AI for chronic disease monitoring, you should compare leading remote patient monitoring (RPM) and chronic care management (CCM) vendors like HealthSnap, BioIntelliSense, ThoroughCare, and ChronicCareIQ.
Top AI Vendors for Chronic Disease Monitoring
| Vendor | Core Model | Best Fit For |
|---|---|---|
| HealthSnap | Hybrid (AI platform + clinical care navigation) | Larger practices and health systems needing integrated lifestyle and biometric data. |
| BioIntelliSense | Medical-grade wearable + continuous predictive AI | Multi-parameter vital sign tracking for high-risk home recovery and chronic patients. |
| ThoroughCare | Software-only analytics and care coordination | In-house care teams running multiple simultaneous wellness and chronic programs. |
| ChronicCareIQ | Software automation | Practices combining RPM and CCM workflows into a single dashboard. |
Key Comparison Criteria
If you can share which specific chronic conditions (such as diabetes, hypertension, or heart failure) and what type of care setting you represent, I can narrow down these vendor options further.
